About Us
Our Mission
Solidus' mission for the pharmaceutical industry is to improve the process of new drug development by providing proprietary decision-enabling technology to enhance drug safety, efficiency, cost, and, thereby, productivity from investment in new drug research and development.
Our History
Solidus Biosciences, Inc., a Delaware registered company, was founded in August 2002 to commercialize the DataChip/MetaChip biocatalytic platform to profile chemical compound toxicity to enhance decision-making in of support new product development in the pharmaceutical, biotechnology, cosmetics, and agrichemical industries. The company's core competence is its extensive knowledge and understanding of and experience with biocatalysis, cell culture and materials science to produce analytical products to evaluate drug safety by emulating human biological functionality. These capabilities, in combination with those in automation, permit miniaturization of design and processes to enable efficient materials usage and resulting application in the early drug development stages.
Professors Douglas S. Clark and Jonathan S. Dordick founded the company. Drs. Dordick and Clark are leaders in the field of biocatalysis with particular expertise in drug discovery. Together they have nearly 40 years of biocatalysis, cell culture, bioengineering, and drug discovery related research experience. In a prior venture (EnzyMed, Inc.), Drs. Clark and Dordick successfully converted their academic research to commercial product development.
The Company is the exclusive licensee of the worldwide patent for the DataChip/MetaChip technology held by Rensselaer Polytechnic Institute and the University of California at Berkeley. It has been awarded nearly $4.0 million in SBIR/STTR grants from the National Institutes of Health and the National Science Foundation to assist development of its technology. The Company's offices and laboratories located San Francisco, California.